Cytokeratin 18 in nonalcoholic fatty liver disease: value and application.

IF 3.9 3区医学 Q1 PATHOLOGY Expert Review of Molecular Diagnostics Pub Date : 2024-10-10 DOI:10.1080/14737159.2024.2413941

Yuan Wu, Jing Zhou, Jun Zhang, Hongshan Li

{"title":"Cytokeratin 18 in nonalcoholic fatty liver disease: value and application.","authors":"Yuan Wu, Jing Zhou, Jun Zhang, Hongshan Li","doi":"10.1080/14737159.2024.2413941","DOIUrl":null,"url":null,"abstract":"Introduction: Nonalcoholic fatty liver disease (NAFLD) is a common metabolism-related disease worldwide. Although studies have shown that some medications may be effective for treating NAFLD, they do not satisfy the medical requirements, and lifestyle changes are the most basic strategy. Thus, early detection of NAFLD and timely lifestyle interventions are highly important.Areas covered: The traditional diagnostic methods for NAFLD are limited by accuracy, cost, and security issues. Cytokeratin 18 (CK18), which is a marker of apoptosis and overall cell death, is an excellent biomarker for NAFLD. Liver fat accumulation in NAFLD triggers the activation of caspases, which increases the CK18 cleavage and its release into the blood. CK18 can help diagnose different stages of NAFLD, especially the nonalcoholic steatohepatitis (NASH) stage. In evaluating the efficacy of the NAFLD treatment and predicting the risk of NAFLD-related diseases, CK18 plays a significant role.Expert opinion: CK18 can non-invasively monitor the pathological conditions of NAFLD patients and provide new hope for the early diagnosis of NAFLD. Adding CK18 to the NAFLD diagnostic criteria that are widely used in clinical settings may be efficient for the detection of NAFLD and early effective intervention.","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":" ","pages":"1-14"},"PeriodicalIF":3.9000,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Molecular Diagnostics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737159.2024.2413941","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Nonalcoholic fatty liver disease (NAFLD) is a common metabolism-related disease worldwide. Although studies have shown that some medications may be effective for treating NAFLD, they do not satisfy the medical requirements, and lifestyle changes are the most basic strategy. Thus, early detection of NAFLD and timely lifestyle interventions are highly important.

Areas covered: The traditional diagnostic methods for NAFLD are limited by accuracy, cost, and security issues. Cytokeratin 18 (CK18), which is a marker of apoptosis and overall cell death, is an excellent biomarker for NAFLD. Liver fat accumulation in NAFLD triggers the activation of caspases, which increases the CK18 cleavage and its release into the blood. CK18 can help diagnose different stages of NAFLD, especially the nonalcoholic steatohepatitis (NASH) stage. In evaluating the efficacy of the NAFLD treatment and predicting the risk of NAFLD-related diseases, CK18 plays a significant role.

Expert opinion: CK18 can non-invasively monitor the pathological conditions of NAFLD patients and provide new hope for the early diagnosis of NAFLD. Adding CK18 to the NAFLD diagnostic criteria that are widely used in clinical settings may be efficient for the detection of NAFLD and early effective intervention.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

细胞角蛋白 18 在非酒精性脂肪肝中的价值和应用。

简介非酒精性脂肪肝（NAFLD）是全球常见的代谢相关疾病。尽管研究表明，一些药物对治疗非酒精性脂肪肝可能有效，但并不能满足医疗要求，改变生活方式才是最基本的策略。因此，非酒精性脂肪肝的早期发现和及时的生活方式干预非常重要：非酒精性脂肪肝的传统诊断方法受到准确性、成本和安全性等问题的限制。细胞角蛋白 18（CK18）是细胞凋亡和整体细胞死亡的标志物，是非酒精性脂肪肝的绝佳生物标志物。非酒精性脂肪肝患者的肝脏脂肪堆积会引发caspases活化，从而增加CK18的裂解并将其释放到血液中。CK18 可帮助诊断非酒精性脂肪肝的不同阶段，尤其是非酒精性脂肪性肝炎（NASH）阶段。在评估非酒精性脂肪肝治疗效果和预测非酒精性脂肪肝相关疾病风险方面，CK18 发挥着重要作用：专家观点：CK18可以无创监测非酒精性脂肪肝患者的病理状况，为非酒精性脂肪肝的早期诊断提供了新希望。在临床广泛使用的非酒精性脂肪肝诊断标准中加入CK18，可有效发现非酒精性脂肪肝并进行早期有效干预。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Expert Review of Molecular Diagnostics 医学-病理学

CiteScore

6.60

自引率

0.00%

发文量

审稿时长

1 months

期刊介绍： Expert Review of Molecular Diagnostics (ISSN 1473-7159) publishes expert reviews of the latest advancements in the field of molecular diagnostics including the detection and monitoring of the molecular causes of disease that are being translated into groundbreaking diagnostic and prognostic technologies to be used in the clinical diagnostic setting. Each issue of Expert Review of Molecular Diagnostics contains leading reviews on current and emerging topics relating to molecular diagnostics, subject to a rigorous peer review process; editorials discussing contentious issues in the field; diagnostic profiles featuring independent, expert evaluations of diagnostic tests; meeting reports of recent molecular diagnostics conferences and key paper evaluations featuring assessments of significant, recently published articles from specialists in molecular diagnostic therapy. Expert Review of Molecular Diagnostics provides the forum for reporting the critical advances being made in this ever-expanding field, as well as the major challenges ahead in their clinical implementation. The journal delivers this information in concise, at-a-glance article formats: invaluable to a time-constrained community.